SQ-LIP-000008 · v1.6 (archived) · View current version →
Is lipedema associated with fibromyalgia and other chronic-pain conditions?
Also asked as
- Do people with lipedema have a higher chance of also having fibromyalgia or other chronic pain disorders?
- Is there a link between lipedema and conditions like fibromyalgia and ongoing pain syndromes?
- lipedema fibromyalgia chronic pain conditions association
- Are lipedema patients more likely to develop fibromyalgia and similar chronic-pain illnesses?
- Current answer
- Lipedema is consistently associated with chronic pain and co-occurs with fibromyalgia at frequencies well above general-population estimates, though all data are observational…
- Knowledge state
- Emerging · Evidence confidence: low (GRADE) · Stability: Evolving
- Evidence
- 8 supporting · 0 contradicting · 10 refining / context
- ⚠ none indexed yet — the registry may under-detect disconfirming evidence (a known limitation)
- Main limitation
- All evidence is observational and predominantly cross-sectional with no adjusted or controlled analysis isolating fibromyalgia comorbidity; the wide prevalence range (10–50%)…
- Latest change
- Answer recompiled after human curation of the claim set. · v1.6
- Knowledge freshness
- 84% recent · current evidence base
- Last updated
- 2026-06-02 · v1.6
| Fibromyalgia co-occurrence with lipedema | increased | low (GRADE) | symptom-only |
| ACR-2016 fibromyalgia prevalence ~10–40% in lipedema cohorts; observational, unadjusted, no controls. | |||
| Chronic pain burden in lipedema | increased | low (GRADE) | symptom-only |
| Pain reported by 88–100%; higher than matched controls (70.8%); descriptive only. | |||
| Musculoskeletal/joint pain & migraine | increased | low (GRADE) | symptom-only |
| Joint/knee pain ~56–58%; migraine 7–35% across cohorts; crude prevalences. | |||
| Peripheral vs central pain mechanism | mixed | very_low (GRADE) | symptom-only |
| QST/histology favor peripheral (ECM stiffness, CGRP/NGF), not central sensitization; small studies. | |||
| Systemic inflammation as pain mediator | not demonstrated | low (GRADE) | symptom-only |
| RCT: diet-induced pain reduction not linked to hsCRP/cytokine/fibrosis changes. | |||
| Causal direction / shared mechanism | not demonstrated | very_low (GRADE) | symptom-only |
| No study establishes causality or shared pathophysiology between conditions. | |||
Based on currently indexed evidence, lipedema is consistently associated with chronic pain and co-occurs with fibromyalgia at frequencies well above general-population estimates, though all data are observational, largely cross-sectional, and of low-to-moderate quality; no high-quality (controlled, adjusted) study establishes the association or its causal direction. Multiple cross-sectional studies using ACR 2016 criteria report fibromyalgia prevalence in lipedema cohorts ranging from ~10% to ~40%: approximately 34–35% in two studies (DOI:10.1089/lrb.2023.0038; DOI:10.2147/jpr.s315736), 39.6% in a comparative study where the comorbid lipedema+fibromyalgia subgroup had significantly higher pain (median VAS 60 vs 27, p<0.001) and worse SF-36 quality of life across all 8 domains (DOI:10.47582/jompac.1301253), and a lower 10% in a study primarily contrasting lipedema with Dercum's disease (28%, P=0.0003) (DOI:10.1038/ijo.2016.205); fibromyalgia also appeared as a self-reported comorbidity (n=14) in a survey where 88.3% reported pain (DOI:10.1007/s13555-018-0241-6). Conversely, an earlier study found lipedema in 50% of women already meeting ACR fibromyalgia criteria, with longer fibromyalgia diagnostic delay and younger menarche as risk factors and pain correlated with widespread pain (r=0.62) (DOI:10.1177/02683555251321042). Pain burden in lipedema is substantial: 100% of lipedema patients in one matched-control study reported pain versus 70.8% of controls, with 43.2% reporting severe pain-related disability versus 9.2% (rho≈0.61 with depressive symptoms) (DOI:10.3390/life14030295); a Swiss cohort of 381 patients reported pain in 87.9% and high fatigue in 56.1% (DOI:10.1371/journal.pone.0319099). Musculoskeletal involvement is common—joint/knee pain in ~56–58% (DOI:10.1590/1677-5449.202101981; DOI:10.1111/ddg.15064; DOI:10.3390/jcm14207195), with one large cohort (n=860) reporting joint pain (58%), migraine (35%), and insomnia (36%) but not enumerating fibromyalgia (DOI:10.1111/ddg.15064). Migraine appears as a frequent comorbidity (7–35% across studies), and one retrospective surgical cohort noted 66.7% of patients with prior migraine reported postoperative reduction after liposuction (DOI:10.1111/dth.14534). Mechanistically, the emerging picture favors a peripheral rather than central pain process: cutaneous hypersensitivity and neuropathic features increased with disease stage alongside reduced dermal neuronal density and elevated CGRP/NGF (DOI:10.3390/ijms231810313), and quantitative sensory testing in non-obese women showed reduced pressure pain threshold and increased vibration detection threshold selectively in the affected thigh but not the hand, with no central alterations, implicating ECM stiffness and mechanoceptive amplification (DOI:10.1111/obr.13953). A randomized trial (n=70) found that diet-induced pain reduction was NOT associated with changes in hsCRP, cytokines, fibrosis markers, or ketosis, arguing against systemic inflammation as the pain mediator (DOI:10.1016/j.cdnut.2025.104571). Additional pain-related features include fatigue (~75%) and frequently reported hypermobility, though reported hypermobility prevalence varies widely (50.5% in a surgical series vs 4.2% by Beighton≥5 in the Swiss cohort) (DOI:10.1515/hmbci-2017-0076; DOI:10.1097/gox.0000000000005436; DOI:10.1371/journal.pone.0319099). Causal direction and whether shared mechanisms underlie the co-occurrence remain unestablished.
A synthesis rendered from the currently indexed evidence — versioned, not a verdict.
⚙ AI consolidation: Claude Opus 4.8 · 2026-06-02 — evidence-bounded; the AI does not opine
Answer recompiled after human curation of the claim set.
Knowledge freshness = share of the 19 indexed evidence sources from the last 5 years (newest 2025, oldest 2017) . Low freshness flags an ageing evidence base — not that the answer is wrong.
Evidence over time
supporting contradicting refining / context Each dot is a study, placed by year and coloured by whether the linked claim supports or contradicts the answer. As the surveillance loop runs, claim revisions and new evidence will extend this timeline.
Choose a format (Vancouver default). Citing a version captures the evidence state on that date; this page shows the current version — see version history.
Supporting claims
- SCR-LIP-000021 supporting
Lipedema and fibromyalgia frequently co-occur: a cross-sectional study found lipedema in 50% of women meeting ACR fibromyalgia criteria, with longer fibromyalgia diagnostic delay and younger menarche as risk factors.
Lipedema awareness in fibromyalgia — Bolkan Günaydın et al. (2025) - SCR-LIP-000022 supporting
Knee pain is a common musculoskeletal feature of lipedema, reported by 58.1% of women screening positive for lipedema in a Brazilian population study.
Prevalência e fatores de risco para lipedema no Brasil — Amato et al. (2022) - SCR-LIP-000104 supporting
In a cross-sectional survey of 354 women with lipedema, 35% (124/354) met ACR 2016 diagnostic criteria for fibromyalgia syndrome, and those with fibromyalgia had significantly higher anxiety, depression, and impaired quality of life compared to those without.
Prevalence of Fibromyalgia Syndrome in Women with Lipedema and Its Effect on Anxiety, Depression, and Quality of Life — Cagliyan Turk et al. (2024) · Common and Contrasting Characteristics of the Chronic Soft-Tissue Pain Conditions Fibromyalgia and Lipedema — Angst et al. (2021) - SCR-LIP-000105 supporting
In a cross-sectional study comparing lipedema patients to sex-, age-, and BMI-matched population controls, 100% of lipedema patients reported pain (vs. 70.8% of controls), with 43.2% reporting severe pain-related disability in daily activities vs. 9.2% of controls, and strong correlation between pain severity and depressive symptoms (rho=0.612, p<0.001).
Health Implications of Lipedema: Analysis of Patient Questionnaires and Population-Based Matched Controls — Kempa et al. (2024) - SCR-LIP-000290 supporting
In a comparative observational study, 39.6% (21/53) of lipedema patients met ACR 2016 criteria for fibromyalgia, and the comorbid lipedema+fibromyalgia subgroup had significantly higher pain (median VAS 60 vs 27 for lipedema alone, p<0.001) and worse SF-36 quality-of-life scores across all 8 domains.
DOI:10.47582/jompac.1301253 - SCR-LIP-000291 supporting
In a comparative study, fibromyalgia prevalence was 10% in lipedema patients (versus 28% in Dercum's disease, P=0.0003) and migraines were reported in 7% of lipedema patients (versus 21% in Dercum's, P=0.005), with a mean pain score of 4±2.5 on a 0–10 scale among lipedema patients.
DOI:10.1038/ijo.2016.205 - SCR-LIP-000293 supporting
In a cross-sectional online survey, lipedema patients reported higher frequencies of chronic joint pain (ankles 70%, cervical spine 66%, knees 56%) and multisystem symptoms than lymphedema patients, with 26% recalling frequent childhood limb/back pain versus 12.7% in lymphedema, though differences were not statistically tested.
DOI:10.3390/jcm14207195 - SCR-LIP-000295 supporting
In a survey of lipedema patients, all reported physical complaints including pain (88.3%, mean current NRS 4.2) and fibromyalgia was among the reported comorbidities (n=14), with comorbidities associated with significantly reduced quality of life.
DOI:10.1007/s13555-018-0241-6
Contradictory claims
- None indexed yet.
Refining / context
- SCR-LIP-000058 context
The article discusses the effects of a modified Mediterranean diet on lipoedema patients, noting improvements in their ability to perform daily activities with less fatigue, pain, and anxiety, but does not directly establish a link between lipoedema and fibromyalgia or other chronic-pain conditions.
Potential Effects of a Modified Mediterranean Diet on Body Composition in Lipoedema — Di Renzo et al. (2021) - SCR-LIP-000106 context
In a cohort of 860 lipedema patients, 99% had at least one comorbidity, including joint pain (58%), abnormal menstruation (43%), insomnia (36%), migraine (35%), allergies (33%), depression (31%), and lymphedema (30%), but fibromyalgia was not specifically reported among the listed comorbidities.
Breaking the circle‐effectiveness of liposuction in lipedema — Seefeldt et al. (2023) - SCR-LIP-000107 context
Lipedema is characterized as a painful fat disorder associated with fatigue (reported by ~75% of patients), joint abnormalities, psychosocial distress, and hypermobility in >50% of patients, but the article does not specifically quantify co-occurrence with fibromyalgia or other named chronic-pain conditions.
Lipedema: friend and foe — Torre et al. (2018) - SCR-LIP-000147 refines
In lipedema patients, pain prevalence and von Frey cutaneous hypersensitivity increased with disease stage (60-100% leg pain across stages, painDETECT >19 only in Stage 3), with reduced dermal Tuj-1+ neuronal density in abdomen and elevated CGRP/NGF in Stage 3 tissues suggesting peripheral neuropathic pain and neurogenic inflammation, independent of BMI.
Indications of Peripheral Pain, Dermal Hypersensitivity, and Neurogenic Inflammation in Patients with Lipedema — Chakraborty et al. (2022) - SCR-LIP-000292 context
In a Swiss cohort of 381 lipedema patients, pain was reported by 87.9% (high pain BPI≥7 in 14.2%) and high fatigue (FSS≥4) in 56.1%, but rheumatic comorbidities and chronic-pain-specific conditions such as fibromyalgia were not separately quantified, and joint hypermobility (Beighton≥5) was present in only 4.2%.
DOI:10.1371/journal.pone.0319099 - SCR-LIP-000294 context
In a retrospective cohort of lipedema patients undergoing multistage liposuction, 22.6% had a prior migraine diagnosis, of whom 66.7% reported reduced intensity and/or frequency of attacks postoperatively (p<0.0001).
DOI:10.1111/dth.14534 - SCR-LIP-000296 context
In a randomized trial of 70 females with lipedema and obesity comparing low-carbohydrate versus low-fat low-energy diets, changes in pain were NOT significantly associated with changes in hsCRP, cytokines, fibrosis-associated markers, or ketosis, refuting that diet-induced pain reduction in lipedema is mediated by systemic inflammation.
DOI:10.1016/j.cdnut.2025.104571 - SCR-LIP-000297 context
In a case series of 189 women undergoing lipedema reduction surgery, reported comorbidities included joint hypermobility (50.5%), arthritis (29.1%), depression (22.8%), and migraine (8.4%), but fibromyalgia was not specifically reported and no adjusted analysis of pain-condition associations was performed.
DOI:10.1097/gox.0000000000005436 - SCR-LIP-000298 context
This narrative review of lipedema morphology and pathophysiology states that lipedema leads to chronic pain, swelling, and other discomforts due to bilateral asymmetrical subcutaneous adipose tissue expansion, but it does not specifically examine an association with fibromyalgia or other defined chronic-pain conditions.
DOI:10.3390/biomedicines10123081 - SCR-LIP-000299 refines
Quantitative sensory testing in non-obese women with lipedema showed a 2-fold reduced pressure pain threshold and 2.5-fold increased vibration detection threshold selectively in the affected thigh (quadriceps/patella) but not the hand, with no central alterations, suggesting a peripheral pain mechanism via ECM stiffness and mechanoceptive amplification.
DOI:10.1111/obr.13953
Major uncertainty
All evidence is observational and predominantly cross-sectional with no adjusted or controlled analysis isolating fibromyalgia comorbidity; the wide prevalence range (10–50%) reflects differing populations, ascertainment, and selection bias, and causal direction plus shared-mechanism hypotheses remain unestablished. Mechanistic data point peripherally (ECM stiffness, neurogenic inflammation, not systemic inflammation) which sits in tension with fibromyalgia's central-sensitization framing.
Version history
- SQ-LIP-000008 · v1.6 — 2026-06-02 — Answer recompiled after human curation of the claim set. · view this version
- SQ-LIP-000008 · v1.5 — 2026-05-31 — This update added a second ACR-2016-based fibromyalgia prevalence estimate (39.6%, with markedly worse pain and QoL in the comorbid subgroup) plus a divergent lower estimate (10%), broadening the prevalence range, and introduced mechanistic evidence (QST localizing pain peripherally and a negative RCT excluding systemic inflammation as the pain mediator) that sharpens the contrast between lipedema's apparently peripheral pain and fibromyalgia's central phenotype. · view this version
- SQ-LIP-000008 · v1.4 — 2026-05-31 — Answer recompiled after human curation of the claim set. · view this version
- SQ-LIP-000008 · v1.3 — 2026-05-31 — This update added a mechanistic cross-sectional study showing stage-dependent cutaneous hypersensitivity, reduced dermal neuronal density, and elevated CGRP/NGF, characterizing lipedema pain as peripheral neuropathic/neurogenic-inflammatory and independent of BMI. · view this version
- SQ-LIP-000008 · v1.2 — 2026-05-31 — This update added multiple cross-sectional studies with validated diagnostic criteria that quantified fibromyalgia comorbidity at 34–35% in lipedema populations, documented that 100% of lipedema patients report pain versus matched controls, and provided large-cohort comorbidity data, substantially strengthening and numerically grounding the previously approximate estimate of 'about half' and clarifying that the earlier figure likely reflected a fibromyalgia-enriched sample. · view this version
- SQ-LIP-000008 · v1.1 — 2026-05-30 — This update added context regarding the effects of a modified Mediterranean diet on lipoedema patients, noting improvements in daily activities and pain but not establishing a direct link to fibromyalgia. Answer reviewed and tightened by curator for rigor. · view this version
- SQ-LIP-000008 · v1.0 — 2026-05-30 — founding index (18 claims) · view this version
Key references
DOI:10.1177/02683555251321042 · DOI:10.1590/1677-5449.202101981 · DOI:10.3390/nu13020358 · DOI:10.1089/lrb.2023.0038 · DOI:10.2147/jpr.s315736 · DOI:10.3390/life14030295 · DOI:10.1111/ddg.15064 · DOI:10.1515/hmbci-2017-0076 · DOI:10.3390/ijms231810313 · DOI:10.47582/jompac.1301253 · DOI:10.1038/ijo.2016.205 · DOI:10.1371/journal.pone.0319099 · DOI:10.3390/jcm14207195 · DOI:10.1111/dth.14534 · DOI:10.1007/s13555-018-0241-6 · DOI:10.1016/j.cdnut.2025.104571 · DOI:10.1097/gox.0000000000005436 · DOI:10.3390/biomedicines10123081 · DOI:10.1111/obr.13953